异基因造血细胞移植后皮肤黑色素瘤发生的危险因素
该嵌套病例对照研究纳入140例黑色素瘤病例和557例对照,发现接受全身照射为基础清髓预处理、含美法仑或氟达拉滨的减低强度预处理、急性GVHD伴2级及以上皮肤受累、无皮肤受累的慢性GVHD、角化细胞癌以及居住于较高环境紫外线辐射地区者,移植后黑色素瘤风险显著增加。结果强调对高风险移植幸存者应坚持常规皮肤检查和光防护建议。
要点
- 全身照射为基础清髓预处理与移植后黑色素瘤风险升高相关(OR=1.77)。
- 含美法仑或氟达拉滨的减低强度预处理风险更高(OR分别为2.60和2.72)。
- 急性GVHD伴皮肤受累、慢性GVHD无皮肤受累及角化细胞癌史均增加风险。
核心结论
- 异基因HCT幸存者中,特定预处理方案、GVHD表现、角化细胞癌史及高环境紫外线暴露与黑色素瘤风险升高相关。
- 结果支持对最高风险HCT幸存者坚持常规皮肤检查和光防护建议。
研究设计与样本
- 通过国际血液和骨髓移植研究中心开展的嵌套病例对照研究,纳入140例黑色素瘤病例和557例对照。
- 对照按移植时年龄、性别、原发病和生存时间匹配。
主要发现
- 与以白消安为基础清髓方案相比,全身照射为基础清髓预处理者黑色素瘤风险升高(多变量校正OR=1.77;95%CI 1.00-3.15)。
- 含美法仑的减低强度预处理者风险升高(OR=2.60;95%CI 1.13-6.02)。
- 含氟达拉滨的减低强度预处理者风险升高(OR=2.72;95%CI 1.02-7.30)。
- 急性GVHD伴2级及以上皮肤受累者风险升高(OR=1.92;95%CI 1.19-3.10)。
- 无皮肤受累的慢性GVHD者风险升高(OR=1.91;95%CI 1.03-3.57)。
关键数值与推荐
- 角化细胞癌病史与黑色素瘤风险升高相关(OR=2.37;95%CI 1.16-4.83)。
- 居住于较高环境紫外线辐射地区者风险升高(第三三分位OR=1.64;95%CI 1.01-2.67)。
临床怎么用
- 对接受全身照射为基础清髓预处理、含美法仑或氟达拉滨减低强度预处理、有GVHD相关表现或角化细胞癌史的HCT幸存者,应加强黑色素瘤监测。
- 遵循现行监测指南,进行常规皮肤检查并提供光防护建议。
局限性
- 缺乏个体水平紫外线辐射暴露数据。
- 缺乏黑色素瘤临床特征数据。
- 并非所有病理报告可供审阅,黑色素瘤分类可能存在误判。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Melanoma risk is increased after allogeneic hematopoietic cell transplantation (HCT), but specific risk factors are unknown. OBJECTIVE: Investigate risk factors for melanoma after allogeneic hematopoietic cell transplantation. METHODS: We conducted a nested case-control study of 140 melanoma cases and 557 controls (matched by age at HCT, sex, primary disease, survival time) through the Center for International Blood and Marrow Transplant Research. RESULTS: Melanoma risk was significantly increased among HCT survivors who received total body irradiation-based myeloablative conditioning (multivariable adjusted odds ratio [OR] = 1.77; 95% confidence interval [CI] = 1.00-3.15) or reduced-intensity conditioning containing melphalan (OR = 2.60; 95% CI = 1.13-6.02) or fludarabine (OR = 2.72; 95% CI = 1.02-7.30) versus busulfan-based myeloablative regimens; were diagnosed with acute graft-versus-host disease (GVHD) with stage 2+ skin involvement (OR = 1.92; 95% CI = 1.19-3.10), chronic GvHD without skin involvement (OR = 1.91; 95% CI = 1.03-3.57), or keratinocytic carcinoma (OR = 2.37; 95% CI = 1.16-4.83); and resided in areas with higher ambient ultraviolet radiation (ORtertile3 = 1.64; 95% CI = 1.01-2.67). LIMITATIONS: Data on individual-level ultraviolet radiation exposure and clinical data on melanoma characteristics were lacking. Additionally, misclassification of melanoma is possible as not all pathology reports were available for review. CONCLUSION: These results emphasize the importance of adherence to current surveillance guidelines (routine skin examination, photoprotection recommendations), particularly for HCT survivors at highest risk.
引用
- Herr MM, Curtis RE, Tucker MA, et al. Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. J Am Acad Dermatol. 2019. PMID: 31654664. doi:10.1016/j.jaad.2019.10.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。